anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Sivifene
Trial phase: Phase 2
SMILES: O=[N+]([O-])c1ccc(NN=C(c2ccc(O)cc2)c2ccc(O)cc2)c([N+](=O)[O-])c1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 75
Group description: Experimental A007
Eligibility criteria:
Inclusion Criteria:

Patients may be enrolled in the study only if they meet all of the following criteria:

18 years of age or older
The patient or her authorized representative must sign and date an Ethical Review Board-approved informed consent document. All aspects of the protocol must be explained and written informed consent obtained.
Patients must have histological proof of HSIL (CIN 2/3) disease documented.
Cervical swabs must test positive for HPV (by Hybrid Capture 2).
Patients must have a Hb ≥ 9 g/dl, a peripheral WBC ≥ 3000 mm3 and platelet counts ≥ 100,000 mm3.
Normal hepatic and renal functions - AST and ALT < 2.5 x ULN and creatinine < 1.5 x ULN, respectively.
Females of childbearing potential must use one of the following birth control methods during the treatment period and 2 weeks thereafter: oral, implantable, injectable contraceptives; abstinence (celibacy). Contraceptive sponges, IUD, spermicides, sponges, condoms, or partner's vasectomy are not acceptable methods of birth control.

Exclusion Criteria:

Patients will be excluded from the study for any of the following preexisting reasons:

Patients with LSIL (CIN 1) or invasive squamous cell carcinoma (SCC).
SIL (CIN) involving the endocervix as determined by endocervical curettage, or otherwise not amenable to adequate colposcopic follow-up evaluations, i.e. unsatisfactory colposcopy.
CIN 3 involving more than two cervical quadrants on colposcopy.
Patients treated for cervical SIL within the past year.
Patients with other malignancy (except for non-melanoma skin) within the past 5 years.
Patients with any active infections (including HIV) other than HPV.
Patients with known clinically relevant immunological deficiency.
Concurrent treatment with cytotoxic, radiation, or immuno-stimulative therapy, or with systemic corticosteroids at a dose of > 5 mg/d of prednisone (or its equivalent).
Participation in another investigational medication trial concurrently or within 30 days, or prior participation in an HPV vaccine trial. Treatment within the last 30 days with a medication that has not received regulatory approval at the time of study entry.
Concomitant use of topical vaginal medications.
Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.
History of allergy or hypersensitivity to cosmetics, toiletries, or other topical or dermatologic products.
Pregnant or lactating females who are nursing and will not consent to cease nursing.
Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
Intervention: Mifepristone
Trial phase: Not Applicable
ATC code: G03XB01 | G03XB51
SMILES: [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients receive mifepristone one day before and for 5 additional days after starting ECT

Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.
Eligibility criteria:
Inclusion Criteria:To be considered for participation in the study, subject must meet all of the following criteria:

1. Meets DSM-IV criteria for Major Depressive Episode without psychotic features.

2. 18-75 years of age and able to provide legal consent. 3. Referred to Stanford ECT service by treating physician for bilateral electroconvulsive therapy with inpatient hospitalization.

4. Completed process for consenting to the clinical use of ECT according to California State law.

5. Females of childbearing potential must be using a double-barrier method of contraception during the study and for 30 days after the study (modified 6-2003) Exclusion Criteria:Subjects will be excluded from participation if they meet any of the following criteria:

Treatment with ECT in the 6 months prior to screening.
Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening.
Use of alcohol or illegal drugs within seven days of randomization or during study.
Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by investigator.
Use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.
Use of any investigational treatment within 30 days of randomization.
Current pregnancy.
Current lactation.
Previous allergic reaction to mifepristone or drugs of similar chemical structure. (added 6-2003)
Use of any oral contraceptives or other drugs that may result in adverse drug-mifepristone interaction effects. A 30-day wash out period for oral contraceptives is required before mifepristone begins.
Intervention: Lovastatin
Trial phase: Phase 2
ATC code: C10AA02 | C10BA01
SMILES: [H][C@@]12C(=C[C@H](C)C[C@@H]1OC(=O)[C@@H](C)CC)C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Lovastatin: 80 mg; 40 mg orally twice per day
Eligibility criteria:
INCLUSION CRITERIA

Female

Increased inherited risk of breast cancer, as defined by:

Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation
Family history conveying at least a 2-fold increase in breast cancer risk
ECOG performance status 0
Normal organ and marrow function, including complete blood count and comprehensive metabolic panel within normal institutional limits
Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks per week.

EXCLUSION CRITERIA

Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage III or lower breast cancer > 2 years ago)
Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III or cancer without evidence of recurrence for 5 years
Initial mammogram, breast MRI, or clinical breast examination prompts recommendation for biopsy by study investigators.
Evidence of malignant cytology on initial rpFNA.
Use of other investigational agents.
Use of tamoxifen or selective estrogen response modifiers (SERMS), including raloxifene, within the last 2 years.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.
Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates or niacin, (unless discontinued for study participation)
No evidence of active liver disease, nor elevation of serum transaminases (prior history of liver disease, if not currently active, is not an exclusion)
No evidence of myopathy or myositis, including symptoms of generalized muscle aches or weakness, muscle tenderness, or elevation in creatine phosphokinase.
Lactating (breastfeeding)
Intervention: OMEGA-3-ACID ETHYL ESTERS
Trial phase: Phase 4
ATC code: C10AX06
SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 68
Group description: lovaza

omega-3 acid ethyl esters: 4 q qd

omega-3 acid ethyl esters: 4 g qd
Eligibility criteria:
Inclusion Criteria:

40 and 69 years of age Male or female (without hormonal cycling as described below) BMI > 25 Fasting serum triglycerides > 150 mg/dL Ratio of TG/HDL-C > 3.5

Exclusion Criteria:

BMIs > 40 kg/m2 TG > 750 mg/dL HDL-C < 10 mg/dL Presence of other secondary causes of dyslipidemia or hyperglycemia such as hepatic, renal, thyroid or other endocrine diseases History of hypersensitivity to niacin or fish oils History of gout, hepatitis, peptic ulcer or cardiovascular disease Presence of diabetes mellitus, whether controlled by diet or drugs. (We will eliminate subjects with undiagnosed diabetes by screening for fasting glucose > 126 mg/dL) Use of any dietary supplements providing more than 50 mg of niacin or 100 mg of n-3 FA Use of any herbal preparations or weight-loss products Taking any lipid-lowering drugs for at least four weeks prior to screening for the study Medically-required treatment with nitrates, calcium channel blockers, or adrenergic blocking agents (per the Niaspan package insert) Hemoglobin < 12 g/dL (owing to the significant amount of blood being drawn) LDL-C > 145 mg/dL. (This restriction will prevent the randomization of any subject whose LDL-C levels, if assigned to an n-3 FA group, might rise by 10% and thus exceed 160 mg/dL) Known substance abuse Participation in a clinical drug trial anytime during the 30 days prior to screening Anyone whom the investigators judge to be a poor candidate
Intervention: Omeprazole
Trial phase: Phase 4
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: Upon successful completion of the run-in period, participants in the esomeprazole arm were given the compound at a dose of 40mg for 12 weeks. All participants were instructed to take their study medication 30 minutes before breakfast and 30 minutes before dinner. Esomeprazole was supplied by the investigational pharmacy at the University of North Carolina as blue capsules without identifying features.
Eligibility criteria:
Inclusion Criteria:

males and females (of non-childbearing potential. ie-surgically sterile, or willing to use an approved form of birth control) between the ages of 18 and 70 who speak and write in English,
chronic cough (> 8 wks/another article used > 6 wks) with symptom severity criteria of 2 or greater on the Fisman Cough Severity Score and 3 or greater or the Fisman Cough Frequency Score, and,
failure to respond to post nasal drip therapy.

Exclusion Criteria:

abnormal chest x-ray,
patients taking H2 blockers within the previous 3 days or PPI's within the previous 7 days,
failure to respond to past PPI therapy given for cough that lasted at least 12 weeks,
use of an investigational drug within the past 30 days,
previous surgical antireflux or non-surgical endoscopic anti-reflux procedure (ex., Stretta or endoscopic sewing device),
previous aerodigestive malignancy,
current smokers, or ex-smokers (defined as those who quit smoking less than 3 months prior to study enrollment or those who have quit, but have a 20 pack year smoking history),
upper respiratory infection within 8 weeks prior to study enrollment,
current use of a B- blocker, ACE-I, or anticholinesterases at time of enrollment.
Intervention: Genistein
Trial phase: Phase 2 | Phase 3
SMILES: O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 71
Group description: Supro drink once daily for 3 days prior to coronary angiography

Genistein: Drink taken once daily
Eligibility criteria:
Inclusion Criteria:

Aged 30-75 years
Patients requiring diagnostic coronary angiography
Presence of coronary artery disease on angiogram but with at least one non-obstructed (lesions <70% narrowed compared with the adjacent normal part of the vessel) atheromatous vessel (confirmed at diagnostic cardiac catheterisation)
Female patients must be postmenopausal (FSH>40 IU/L)
Willing to give informed, written consent

Exclusion Criteria:

Age <30 or >75 years
Allergy to radiographic contrast media
Sino-atrial disease or significant bradycardia
Concomitant medication with persantin (dipyridamole) or theophyllines
Asthma
Hypertension
Left ventricular hypertrophy or dysfunction (clinical/ECG/echo/CXR)
Female patients with FSH<40 IU/L (postmenopausal)
Female patients currently taking hormone therapy, or who have taken hormone therapy in previous 6 months
Unwilling to give written informed consent
Participation in another study within previous 60 days
Intervention: Pirfenidone
Trial phase: Phase 3
ATC code: L04AX05
SMILES: Cc1ccc(=O)n(-c2ccccc2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 171
Group description: pirfenidone, total daily dose of 2403 mg/day, given as 3 divided doses 3 times/day
Eligibility criteria:
Primary Inclusion criteria:

diagnosis of idiopathic pulmonary fibrosis
40 to 80 years of age
Forced Vital Capacity ≥ 50% predicted value
carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value
either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90% predicted value
no improvement in past year
able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more than 6 liters per minute supplemental oxygen

Primary Exclusion criteria:

unable to undergo pulmonary function testing
evidence of significant obstructive lung disease or airway hyper-responsiveness
in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization
active infection
liver disease
cancer or other medical condition likely to result in death within 2 years
diabetes
pregnancy or lactation
substance abuse
personal or family history of long QT syndrome
other IPF treatment
unable to take study medication
withdrawal from other IPF trials
Intervention: Denintuzumab mafodotin
Trial phase: Phase 4
SMILES: CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(Cc1ccccc1)C(=O)O)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C(=O)CCCCCN1C(=O)CC(SCC(N)C(=O)O)C1=O)C(C)C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 92
Group description: Intravenous Immunoglobulin

Intravenous Immunoglobulin: Intravenous Immunoglobulin
Eligibility criteria:
Inclusion Criteria:

All newborns with a gestational age equal or higher than 32 weeks, with a Rh (D) positive blood type, children of sensitized Rh (D) negative mothers, regardless if they were submitted or not to an intra-uterus transfusion.

Exclusion Criteria:

Newborns in serious condition, hydropic, hemodynamically instable or with indication for exchange transfusion at birth. The indications for exchange transfusion at birth are: presence of bilirubin in the umbilical cord higher or equal to 4mg%; hydrops, cardiac insufficiency secondary to severe anemia.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 92
Group description: Normal Saline solution

Normal saline solution: Normal saline solution 10 ml/Kg
Eligibility criteria:
Inclusion Criteria:

All newborns with a gestational age equal or higher than 32 weeks, with a Rh (D) positive blood type, children of sensitized Rh (D) negative mothers, regardless if they were submitted or not to an intra-uterus transfusion.

Exclusion Criteria:

Newborns in serious condition, hydropic, hemodynamically instable or with indication for exchange transfusion at birth. The indications for exchange transfusion at birth are: presence of bilirubin in the umbilical cord higher or equal to 4mg%; hydrops, cardiac insufficiency secondary to severe anemia.
Intervention: H-Phe-phe-OH
Trial phase: Phase 3
SMILES: NC(Cc1ccccc1)C(=O)NC(Cc1ccccc1)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 151
Group description: Eligible participants received aqueous nasal spray of Fluticasone furoate 100 micrograms (mcg) once daily for 6 weeks in a randomized manner. Dose was administered by alternately spraying one spray into each nostril followed by a second spray into each nostril for 42 days. Participants were followed-up telephonically, up to 5 days after the last dose of the study drug.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of perennial allergic rhinitis (PAR).
Must comply with study procedures and be literate.

Exclusion Criteria:

Significant concomitant medical conditions.
Use of corticosteroids.
Use of allergy and other identified medications during the study.
Current tobacco use or tobacco use within the past year.
Exposure to an investigational study drug within the past 12 months.
Clinically significant abnormal electrocardiograms (ECG) or laboratory abnormality.
Intervention: Sitagliptin Phosphate
Trial phase: Phase 3
SMILES: NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=P(O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 352
Group description: The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily.
Eligibility criteria:
Inclusion Criteria:

Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the values established by the study such as an Hemoglobin A1c (HbA1c) >=7.5% and <=11% and a Fasting Plasma Glucose (FPG) >=130 mg/dL and <=280 mg/dL

Exclusion Criteria :

Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12 months
Intervention: Atorvastatin
Trial phase: Phase 3
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 298
Group description: Atorvastatin 10 mg, orally, once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL

Exclusion Criteria:

Pregnant or lactating women, or women intending to become pregnant
Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)
Human immunodeficiency virus (HIV) positive
Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty
Active or chronic liver disease
Intervention: Atorvastatin
Trial phase: Phase 3
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 439
Group description: Atorvastatin 20 mg, orally, once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL

Exclusion Criteria:

Pregnant or lactating women, or women intending to become pregnant
Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)
Human immunodeficiency virus (HIV) positive
Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty
Active or chronic liver disease
Intervention: Atorvastatin
Trial phase: Phase 3
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 437
Group description: Atorvastatin 40 mg, orally, once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL

Exclusion Criteria:

Pregnant or lactating women, or women intending to become pregnant
Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)
Human immunodeficiency virus (HIV) positive
Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty
Active or chronic liver disease
Intervention: Atorvastatin
Trial phase: Phase 3
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 433
Group description: Atorvastatin 80 mg, orally, once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL

Exclusion Criteria:

Pregnant or lactating women, or women intending to become pregnant
Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)
Human immunodeficiency virus (HIV) positive
Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty
Active or chronic liver disease
Intervention: Chloraprep
Trial phase: Phase 3
SMILES: CC(C)O.NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)CC(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 409
Group description: Skin at surgical site preoperatively scrubbed with an applicator that contained 2% chlorhexidine gluconate and 70% alcohol
Eligibility criteria:
Inclusion Criteria: Adult patients who are scheduled for a clean-contaminated surgical procedure of the alimentary or respiratory tract will be eligible for participation. A clean-contaminated wound is one that is entered under controlled conditions without unusual contamination.

-

Exclusion Criteria: Patients will be excluded form the study if: (1) they are unable or unwilling to give informed consent; (2) the patient is less than 18 years of age; (3) there is evidence of pre-existing infection at or adjacent to the operative site; (4) a break in sterile technique occurs; (5) the patient has a history of allergy to chlorhexidine, alcohol or iodophors.

-
Intervention: Tamoxifen
Trial phase: Phase 2
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
Eligibility criteria:
Inclusion Criteria:

Ductal carcinoma in situ (DCIS) confirmed by excisional or needle biopsy
Size: < 3 cm on mammogram
Unicentric disease
Ability to place MammoSite device at time of lumpectomy or within 4 weeks of lumpectomy
Patient Age: ≥ 18 years, no upper limit
Life expectancy > 5 years

Exclusion Criteria:

Prior history of cancer other than basal or squamous cell skin cancer or in situ cancer of the cervix
Pregnant or breast feeding
Multicentric disease
Diagnosis of collagen vascular diseases, such as systemic lupus erythematosis, scleroderma, or dermatomyositis